Assay Development. RMS shall be responsible for and shall conduct the Assay Development as set forth in the Project Plan, including the Clinical Validation of the RMS Product.
Assay Development. A Work Package may include the development of assays (including immunogenicity and potency/release assays), as will be described in the IPDP.
Assay Development. (a) The Screening Committee will allocate responsibilities between the parties for specific assay development tasks. In general, Neurocrine will develop the appropriate biochemical and/or cellular reagents for the assay and provide necessary quantities to Caliper for LabChip Assay development and screening. Initially, Caliper will direct work to adapt the assay into the LabChip format. Over time, the parties expect that Neurocrine will assume an increasing role in LabChip Assay development. The parties will arrange for Neurocrine scientists to train in LabChip Assay development at Caliper and/or for certain LabChip Assay development tools to be provided to Neurocrine. The Screening Committee will determine, or establish criteria for others to determine, when a LabChip Assay is ready for screening on Caliper's high throughput system.
(b) Caliper and Neurocrine shall each use commercially reasonable efforts to collaboratively develop LabChip Assays for the Targets selected by the Screening Committee. The parties intend to [ * ]. Therefore, the parties have [ * ]. The parties may mutually agree to pursue such research for certain Targets, but Caliper shall not be required under this Agreement to [ * ].
Assay Development. Scopus Biopharma will contract with a Contract Research Organization (CRO) to develop and validate bioanalytical methods for rat, dog, and human plasma.
Assay Development. For each Assay, BMS shall make a milestone payment to Exelixis of [ * ] after BMS' acceptance of such Assay pursuant to Section 3.5(a).
Assay Development. In the event that that Pharmacopeia shall conduct any additional assay validation as provided in Section 2.3, Organon shall pay to Pharmacopeia an amount equal to the number of FTE’s to be utilized for such assay development multiplied by Pharmacopeia’s FTE Rate for the agreed period of such assay development program. Solely for purposes of this Section 6.2, Pharmacopeia’s “FTE Rate” shall be ***. In addition, in the event Organon agrees to the modification of an Assay, Organon shall reimburse Pharmacopeia for the cost of any reagents that Pharmacopeia needs to obtain to conduct its activities pursuant to this Section. Payments under this Section shall be made within thirty (30) days of receipt of an invoice.
Assay Development. LabChip Assays for Amgen's Targets will be developed collaboratively by the parties or by Amgen independently, as determined by Amgen. In general, Amgen will [ * ]. Initially, Caliper will be primarily responsible for adapting the assay to the LabChip format. Over time, the parties expect that Amgen will [ * ].
Assay Development. This cell based assay is based on HTRF® technology (Homogeneous Time-Resolved Fluorescence). It is a competitive immunoassay that uses cAMP labeled with the d2 acceptor flourophore and an anti-cAMP antibody labeled with Europium Cryptate. The FRET signal decreases as cAMP concentration rises.
1. Seed 5 μl CHO-K1/CB2 cells into a 384-well low volume plate, 3,000 cells per well.
2. Add 5 µl compound (diluted in buffer with 0.25% DMSO) to each well and incubate the plate for 30 min at RT.
3. Add 5ul of cAMP-d2 conjugate solution to each well.
4. Add 5μl of cAMP-AB lysis buffer solution to each well.
5. Incubate the plate in the dark for one hour at RT. EC50 1.137e-007 L o g ( C P - 5 5 9 4 0 ) , M R a tio 6 6 0 /6 2 0
6. Read the plate Varioskan (Thermo).
Figure 1. CP-55940-induced concentration-dependent stimulation of intracellular cAMP in CHO-K1/CNR2 cells. The EC50 of CP-55940 on this cell was 0.11 μM. Ratio = A660nm/B620nm x 104
Assay Development. In the event that, at Company’s request, Ligand shall conduct any additional assay development as provided in Section 2.3, Company shall pay to Ligand an amount equal to the number of FTE’s to be utilized for such development multiplied by Ligand’s FTE Rate for the agreed period of such development program. For purposes of this Section 6.2, Ligand’s “FTE Rate” shall be [***] dollars ($[***]) per FTE per month. Payments under this Section shall be made within [***] ([***]) days of receipt of an invoice.
Assay Development. It is anticipated that the Assay has been developed and validated by Organon prior to validation by Pharmacopeia. An Assay shall be considered validated if it meets the criteria set in Exhibit A. On a Target-by-Target basis, Pharmacopeia shall provide up to one (1) FTE month without additional charge to Organon for validation of the Assay for a particular Target. Insofar as the Assay requires additional development by Pharmacopeia or the use of any key reagents that have not been supplied by Organon, the Parties shall mutually agree on the payment of additional fees pursuant to Section 6.2. The Parties agree that all improvements and modifications directly relating to the Assay (collectively the "Assay Improvements") made solely by Pharmacopeia shall be owned by Pharmacopeia. All Assay Improvements that are made jointly by the Parties shall be jointly owned by the Parties. Each Party agrees to grant to the other Party license rights in its interest in Assay Improvements as provided herein.
